Sponsors

Sonix Medical Devices, Inc., is a US-based medical devices company focused on developing non-invasive products and technologies that can prevent and treat infections with the goal of saving millions of lives globally.  Sonix-A8 is an innovative antibacterial technology that prevents and treats bacterial infections and combats Antimicrobial Resistance (AMR) without the use of antibiotics. ‘Sonix-A8’ is a patented breakthrough technology that prevents and controls Surgical Site Infections (SSI’s) and Hospital Acquired Infections (HAI’s). This technology kills bacteria, including superbugs like MRSA, and is effective on and below the skin surface, where traditional treatments can’t reach.  The technology platform completely destroys biofilms and combats AMR.

The first company to develop an innovative medical device that can be used safely by professionals and patients to prevent and treat infections by killing bacteria without having to use antibiotics and ending the Antimicrobial Resistance (AMR) cycle.

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. The Company is developing novel antimicrobial drugs from its “in-house” XF platform and also from recently acquired Biotherapeutic products that harness beneficial components of the human microbiome. We have two exciting late stage clinical assets and a range of earlier research programmes. XF-73 nasal is our novel Phase 2b clinical asset for the prevention of post-surgical Staphylococcal infections which reported positive top-line data in Q1 2021. The Phase 2b trial achieved it’s primary endpoint with >99% nasal bacterial load reduction (p<0.0001) by the XF-73 nasal gel, with an excellent safety profile and no treatment related adverse events reported. Further information on the results of the trial can be found here. Our XF drug platform acts via an ultra-rapid action that kills targeted bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance. Destiny Pharma also recently acquired global rights to NTCD-M3 for the prevention of recurring Clostridioides difficile gut infections that is planned to start Phase 3 studies in 2022. Destiny Pharma is also collaborating with SporeGen Limited on a novel treatment for the prevention of COVID-19 and similar respiratory viral infections using a Bacillus based approach. This project is at the preclinical development stage as are several earlier XF projects. The Company will look to enter selected partnerships to develop its assets and also apply for non-dilutive sources of grant and governmental funding, as it has done in the past, to assist in the development of its portfolio.

Nature has the answer. Designing revolutionary products to naturally and effectively support the immune system in fighting bacteria and infections in a post-antibiotic resistance world. PostABR®

A strategy to accelerate global efforts towards universal health coverage and health emergency response Our strategy seeks to harness the momentum around testing for COVID-19, exploiting emerging digital innovations, and building on our organization’s 20-year experience as a product development partnership focused on diagnosis of tuberculosis (TB), malaria and fever management, hepatitis C, and neglected tropical diseases (NTDs).

Day Zero Diagnostics is developing rapid, whole genome sequencing-based diagnostics to modernize infectious disease diagnosis and treatment. We are harnessing the power of the genome to build technologies that both precisely identify the species and provide the comprehensive antibiotic susceptibility / resistance profile of a bacterial infection within hours, rather than days, so that patients can be treated with the most effective antibiotic quickly. Faster treatment with the right antibiotic saves lives and reduces the cost and complications associated with extended episodes of care.

Madam Therapeutics is a technology platform company and develops novel anti-microbial agents which are fast acting, attack biofilms, and are less likely to give rise to resistance. With our novel AI approach we can mine our large portfolio for either small spectrum and broad spectrum inti-microbial peptides with a good safety profile. Madam Therapeutics follows a ‘One Health’ approach for development of its products developing distinct products for human and veterinary use.

ILSE is a life science technology accelerator, business incubator and a science-driven research institute that works in partnership with innovators, affiliated academic and biomedical institutions. ILSE has joined the CARB-X Global Accelerator Network as an accelerator to provide knowhow, diagnostics expertise, business strategy and other support to CARB-X’s growing portfolio of innovative antibacterial development projects.